Dementia Research Studies
Research is an important component of the work performed by the Memory Disorders Clinic at the University of North Carolina Chapel Hill. In addition to providing important clinical care to the North Carolina community, the Memory Disorders Clinic coordinates a number of research studies investigating memory disorders. Listed below are some ongoing studies:
The NC Registry for Brain Health is a mailing list of people who are interested in learning about ongoing research studies in North Carolina that are designed to improve brain health and prevent conditions such as Alzheimer’s disease (AD).
Contact: Johanna Silbersack, (919) 843-3085
The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers gain a better understanding of the biology behind LBD.
Contact: Jessica Ferrall, (919) 962-8852
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials.
The Duke University and the University of North Carolina Alzheimer’s Disease Research Center (Duke/UNC ADRC) brings together leading researchers in Alzheimer’s disease and related dementias across two major research institutions.
The ADRC aims to catalyze and support research, innovations in clinical care and academic work force development (with North Carolina Central University, East Carolina University and UNC Pembroke as partner institutions) in this field. Their ultimate purpose is to reduce the burden of Alzheimer’s disease and related dementias regionally and nationally. The outstanding scientific environment at both institutions enables novel research to identify effective methods of prevention and/or early intervention, and to reduce racial and urban/rural disparities associated with dementia. Please visit the ADRC website for more information.
This is a phase 3 double-blind, placebo-controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Contact: Molly Espenan, (919) 843-2387